Switch to
Place Order
Suven Pharmaceuticals Ltd
SUVENPHAR
Health CarePharmaceuticals
SmallcapWith a market cap of ₹12,093 cr, stock is ranked 316
Moderate RiskStock is 2.01x as volatile as Nifty
476.400.28% (+1.35)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
Health CarePharmaceuticals
SmallcapWith a market cap of ₹12,093 cr, stock is ranked 316
Moderate RiskStock is 2.01x as volatile as Nifty
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 29.40 | 7.92 | 1.26% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 32.55 | 4.44 | 0.89% |
Forecast & RatingsDetailed Forecast
100%
Analysts have suggested that investors can buy this stock
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Suven Pharmaceuticals is engaged in Contract Research and Manufacturing Services (CRAMS), Drug Discovery & Development Support Services (DDDSS), Drug Discovery & Research/Clinical Pipeline, and Formulation Development
Investor PresentationView older
View Older PresentationsPeersCompare with peers
Sun Pharmaceutical Industries Ltd
FY PE Ratio
26.61
1Y Return
7.77%
Buy Reco %
92.11
Cipla Ltd
FY PE Ratio
27.21
1Y Return
1.37%
Buy Reco %
67.50
Dr Reddy's Laboratories Ltd
FY PE Ratio
16.60
1Y Return
5.27%
Buy Reco %
55.00
Torrent Pharmaceuticals Ltd
FY PE Ratio
74.09
1Y Return
17.22%
Buy Reco %
67.74
Mankind Pharma Ltd
FY PE Ratio
37.10
1Y Return
0.00%
Buy Reco %
100.00
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Revenue
Profit
All values in ₹ Thousand cr.
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Competition Commission Approves Berhyanda’s Stake Acquisition Of Suven Pharma
1 month ago•Bloomberg Quint
Stocks to watch today — April 21, 2023
1 month ago•The Hindu Businessline
Stocks to Watch: HCLTech, Cyient, Siemens, RIL, Suven Pharma, Voda Idea
1 month ago•Business Standard
Buzzing Stocks: RIL, HCL Tech, Cyient, Suven Pharma and others in the news today
1 month ago•Moneycontrol
CCI Clears Berhyanda’s Stake Acquisition In Suven Pharma
1 month ago•Bloomberg Quint
CCI clears Berhyanda’s 76% stake acquisition in Suven Pharmaceuticals
1 month ago•Business Standard
CCI clears Berhyanda’s acquisition of Suven Pharma
1 month ago•Economic Times
CCI approves Berhyanda’s acquisition of Suven Pharma
1 month ago•The Hindu Businessline
Recent EventsAll events
Analysts/Institutional Investor Meet/Con. Call Updates
Copy of Newspaper Publication
Cash Dividend
Interim • Div/Share: ₹ 1
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant